Trial · NCT01930604
Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis
NCT01930604, Phase 2, Unknown, Carl Swartling
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis. Trials, record NCT01930604. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01930604
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis
- NCT number
- NCT01930604
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 588 participants, estimated
- Lead sponsor
- Carl Swartling
- Conditions
- Hyperhidrosis
- Interventions
- Botox (onabotulinumtoxinA), NeuroBloc/Myobloc (rimabotulinumtoxinB), NaCl (placebo)
- First posted
- 2013-08-29
- Last updated
- 2018-03-05
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | DLQI (Dermatology Life Quality Index) | 3±1 weeks after treatment | The primary endpoint is scores on DLQI-values at follow-up in the Btx A/B treatment groups when compared to the placebo groups. |
| Secondary | AE (Adverse Events) | Up to 12 weeks | Safety by recording of reported adverse events (AE) by the patient at the clinic visits |
| Secondary | Gravimetry | Before treatment and 3±1 weeks after treatment | The amount of sweat is measured gravimetrically. |
| Secondary | HDSS (Hyperhidrosis Disease Severity Scale) | Before treatment and 3±1 weeks after treatment | |
| Secondary | Health outcome (EQ-5D) | Before treatment and 3±1 weeks after treatment | |
| Secondary | LSAS-SR (Liebowitz Social Anxiety Scale-Self Report) | Before treatment and 3±1 weeks after treatment | |
| Secondary | MADRS-S (Montgomery-Asberg Depression Rating Scale-Self report) | Before treatment and 3±1 weeks after treatment | |
| Secondary | Global Assessment of Therapy | 3±1 weeks after treatment | The patient will be asked at the follow-up visit (3±1 weeks after treatment) to give his/her subjective opinion and rate the effect of the treatment using a scale ranging from 1-5. |
| Secondary | DLQI (Dermatology Life Quality Index) | Before treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01930604
GET https://conductscience.org/api/trials/v1/NCT01930604/registered